Table 1 Patient characteristics
From: Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
| Ā | Every-3-weeks platinum | Weekly platinum | P-value | Every-3-weeks cisplatinum | Weekly carboplatinum | P-value |
|---|---|---|---|---|---|---|
| Ā | (Nā=ā144) | (Nā=ā68) | Ā | (Nā=ā138) | (Nā=ā52) | Ā |
Median age (years) | 55.5 | 61.4 | <.001 | 55.4 | 61.9 | <.001 |
ā(IQR) | (48.1ā62.0) | (51.7ā71.6) | (47.6ā61.9) | (52.1ā71.5) | ||
Median follow-up (months) | 21.1 | 23.7 | .40 | 21.1 | 23.7 | .70 |
ā(IQR) | (12.2ā59.0) | (11.8ā38.3) | (12.1ā56.0) | (11.3ā45.1) | ||
Gender | Ā | Ā | .16 | Ā | Ā | .04 |
āMale | 116 (80.6%) | 49 (72.1%) | 112 (81.2%) | 35 (67.3%) | ||
āFemale | 28 (19.4%) | 19 (27.9%) | 26 (18.8%) | 17 (32.7%) | ||
KPS | Ā | Ā | .30 | Ā | Ā | .68 |
āāā„ā70 | 120 (83.3%) | 51 (75.0%) | 116 (84.1%) | 41 (78.9%) | ||
āā<ā70 | 9 (6.3%) | 5 (2.4%) | 9 (6.5%) | 4 (7.7%) | ||
āNot stated | 15 (10.4%) | 12 (17.7%) | 13 (9.4%) | 7 (13.5%) | ||
Comorbidity index | Ā | Ā | .01 | Ā | Ā | <.01 |
āMedium | 104 (72.2%) | 37 (54.4%) | 102 (73.9%) | 27 (51.9%) | ||
āHigh | 40 (27.8%) | 31 (45.6%) | 36 (26.1%) | 25 (48.1%) | ||
Stage | Ā | Ā | .34 | Ā | Ā | .33 |
āI | 0 (0.0%) | 1 (1.5%) | 0 (0.0%) | 1 (1.9%) | ||
āII | 10 (6.9%) | 3 (4.4%) | 9 (6.6%) | 2 (3.9%) | ||
āIII | 33 (22.9%) | 19 (27.9%) | 31 (22.6%) | 10 (19.2%) | ||
āIV | 101 (70.1%) | 45 (66.2%) | 97 (70.8%) | 39 (75.0%) | ||
Alcohol history | Ā | Ā | .39 | Ā | Ā | .35 |
āāā„ā2 drinks/day | 76 (52.8%) | 33 (48.5%) | 73 (52.9%) | 25 (48.1%) | ||
āā<ā2 drinks/day | 36 (25.0%) | 21 (30.9%) | 35 (25.4%) | 17 (32.7%) | ||
āNot stated | 32 (22.2%) | 14 (20.6%) | 30 (21.7%) | 10 (19.2%) | ||
Tobacco history | Ā | Ā | .47 | Ā | Ā | .84 |
āā>ā10 pack-years | 106 (73.6%) | 48 (70.6%) | 101 (73.2%) | 38 (73.1%) | ||
āāā¤ā10 pack-years | 33 (22.9%) | 19 (27.9%) | 32 (23.2%) | 13 (25.0%) | ||
āNot stated | 5 (3.5%) | 1 (1.5%) | 5 (3.6%) | 1 (1.9%) | ||
Primary site | Ā | Ā | .83 | Ā | Ā | .68 |
āHypopharynx | 5 (3.5%) | 4 (5.9%) | 5 (3.6%) | 3 (5.8%) | ||
āLarynx | 31 (21.5%) | 12 (17.7%) | 29 (21.0%) | 9 (17.3%) | ||
āNasopharynx | 14 (9.7%) | 5 (7.4%) | 14 (10.1%) | 3 (5.8%) | ||
āOral Cavity | 38 (26.4%) | 16 (23.5%) | 36 (26.1%) | 11 (21.2%) | ||
āOropharynx | 39 (27.1%) | 20 (29.4%) | 38 (27.5%) | 17 (32.7%) | ||
āOther | 17 (11.8%) | 11 (16.2%) | 16 (11.6%) | 9 (17.3%) | ||
Tumor Stage | Ā | Ā | .27 | Ā | Ā | .10 |
āT0-2 | 44 (30.6%) | 26 (38.2%) | 41 (29.7%) | 22 (42.3%) | ||
āT3-4b | 100 (69.4%) | 42 (61.8%) | 97 (70.3%) | 30 (57.7%) | ||
Nodal Stage | Ā | Ā | .14 | Ā | Ā | .68 |
āN0-2a | 69 (47.9%) | 40 (58.8%) | 67 (48.6%) | 27 (51.9%) | ||
āN2b-3 | 75 (52.1%) | 28 (41.2%) | 71 (51.5%) | 25 (48.1%) | ||
P16 status | Ā | Ā | .11 | Ā | Ā | .07 |
āPositive | 4 (2.8%) | 0 (0.0%) | 4 (2.9%) | 0 (0.0%) | ||
āNegative | 50 (34.7%) | 32 (47.1%) | 49 (35.5%) | 27 (51.9%) | ||
āNot stated | 90 (62.3%) | 36 (52.9%) | 85 (61.6%) | 25 (48.1%) |